Discontinued ProductUnfortunately KD 5170 (Cat. No. 4001) has been withdrawn from sale for commercial reasons.
Class I and II histone deacetylase (HDAC) inhibitor (IC50 = 0.045 μM; EC50 = 0.025 μM in HeLa screening and HeLa cell-based assays, respectively). Exhibits broad spectrum inhibition of HDAC classes I and II in assays using purified recombinant human isoforms. Displays less potent inhibition of HDAC2 (IC50 values are 0.014, 0.020, 0.026, 0.075 and 2.0 μM for HDAC6, HDAC1, HDAC4, HDAC3 and HDAC2 respectively). Displays cytotoxicity against numerous cell lines derived from human tumors. Orally available.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Preparing Stock Solutions
The following data is based on the product molecular weight 451.56. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.21 mL||11.07 mL||22.15 mL|
|5 mM||0.44 mL||2.21 mL||4.43 mL|
|10 mM||0.22 mL||1.11 mL||2.21 mL|
|50 mM||0.04 mL||0.22 mL||0.44 mL|
References are publications that support the products' biological activity.
Feng et al (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol.Cancer Ther. 7 1494 PMID: 18566220
Hassig et al (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad-spectrum antitumor activity in vitro and in vivo. Mol.Cancer Ther. 7 1054 PMID: 18483295
Payne et al (2008) Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor. Bioorg.Med.Chem.Lett. 18 6093 PMID: 18954983
View Related Products by Product Action
Keywords: KD 5170, supplier, antitumor, antitumour, hdacs, histone, deacetylases, inhibitors, inhibits, KD5170, epigenetics, Histone, Deacetylases, Histone, Deacetylases, Tocris Bioscience
Citations for KD 5170
Citations are publications that use Tocris products.
Currently there are no citations for KD 5170.
Reviews for KD 5170
There are currently no reviews for this product. Be the first to review KD 5170 and earn rewards!
Have you used KD 5170?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics Research Bulletin
Produced by Tocris and updated in 2014, the epigenetics research bulletin gives an introduction into mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets including:
- DNA Methyltransferases
- Histone Deacetylases
- Histone Demethylases
- Histone Methyltransferases
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.